KALA BIO, Inc. Common Stock

Day range

$0.19 – $0.20

Open

$0.19

Prev close

$0.19

Volume

207.83K

Market cap

$3.59M

Shares out

19.34M

P/E

—

P/S

—

P/B

0.41

P/FCF

—

ROE

-111.5%

ROA

-95.3%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 22, 2026

• Material agreementsSep 10, 2026

  “On September 3, 2026, KALA BIO, Inc. ... entered into an Exclusive Distribution and Reseller Agreement ... with Virotek, Inc.” The Agreement appoints Kala as “the sole and exclusive distributor and reseller” of Virotek’s genetic testing and screening program for ophthalmology in the United States for an initial five-year term.

• Exchange listingAug 28, 2026

  On August 27, 2026, KALA BIO, Inc. received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that the Staff has determined that the closing bid price of the Company's common stock has been below $1.00 per share for the previous 30 consecutive business days and, as a result, the Company is not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(a)(2).

• Equity activityJul 23, 2026

  On July 22, 2026, the Company filed a prospectus supplement pursuant to Rule 424(b) under the Securities Act of 1933, as amended, relating to the offering of securities pursuant to the Company's effective Registration Statement on Form S-3 (File No. 333-295667).

• Governance documentsMay 7, 2026

  On May 7, 2026, KALA BIO, Inc. (the "Company") filed a Certificate of Amendment (the "Certificate of Amendment") to the Company's Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation") with the Secretary of State of Delaware to effect a 1-for-50 reverse stock split of the shares of the Company's common stock.

• Equity activityMar 4, 2026

  In connection with the issuance of the Younet Shares as described in Item 1.01, the Company relied upon the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and Regulation D promulgated thereunder for transactions not involving a public offering.

Days to cover

1.0

Short interest

1.36M

Avg volume

6.22M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
  neutralGlobeNewswire Inc.· Dec 5, 2025
• Crude Oil Falls Sharply; Carnival Posts Upbeat Earnings
  positiveBenzinga· Sep 29, 2025
• 12 Health Care Stocks Moving In Monday's Intraday Session
  positiveBenzinga· Sep 29, 2025
• Nasdaq Jumps 150 Points; US Pending Home Sales Rise
  positiveBenzinga· Sep 29, 2025
• Kala Bio (KALA) Q2 Loss Widens 15%
  neutralThe Motley Fool· Aug 8, 2025